Publications

Exposure-response of different dosing schedules of naratuximab emtansine in combination with rituximab in Non Hodgkin’s lymphoma

[177Lu]Lu-DPI-4452 & [68Ga]Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors

The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models

A novel antibody drug conjugate linker enabling production of ADCs with high drug to antibody ratios and fast payload release…

The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer

Automated Solid Phase Extraction of Triptorelin using Andrew+ Pipetting Robot for Bioanalytical LC-MS/MS Quantitation

Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large B-cell lymphoma and other Non-Hodgkin’s B-cell lymphomas –…

Is CD37-targeted therapy a viable alternative in the treatment of diffuse large B-cell lymphoma? Interviews with two key opinion leaders

Antimicrobial activity of the new FabI inhibitor Afabicin desphosphono against intraosteoblastic Staphylococcus aureus